This is a working overview of TB-500, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-07 and is reviewed periodically as new material appears.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
They are surrounded by a layer of iridium metal and encased in high-strength graphite blocks. These two materials are corrosion- and heat-resistant. Surrounding the graphite blocks is an aeroshell, designed to protect the entire assembly against the heat of reentering the Earth's atmosphere. The plutonium fuel is also stored in a ceramic form that is heat-resistant, minimising the risk of vaporization and aerosolization. The ceramic is also highly insoluble. The plutonium-238 used in these RTGs has a half-life of 87.74 years, in contrast to the 24,110 year half-life of plutonium-239 used in nuclear weapons and reactors. Due to the shorter half-life, plutonium-238 is about 275 times more radioactive than plutonium-239 (i.e. 17.3 curies (640 GBq)/g compared to 0.063 curies (2.3 GBq)/g). For instance, 3.6 kg of plutonium-238 undergoes the same number of radioactive decays per second as 1 tonne of plutonium-239. Since the morbidity of the two isotopes in terms of absorbed radioactivity is almost exactly the same, plutonium-238 is around 275 times more toxic by weight than plutonium-239. The alpha radiation emitted by either isotope will not penetrate the skin, but it can irradiate internal organs if plutonium is inhaled or ingested. Particularly at risk is the skeleton, the surface of which is likely to absorb the isotope, and the liver, where the isotope will collect and become concentrated. A case of RTG-related irradiation is the Lia radiological accident in Georgia, December 2001.
This makes frequent, small sublingual or rectal doses a very efficient way to create a stable and constant increase in trough levels. A large amount of estradiol consumed sublingually, and especially orally is converted by the GI tract into estrone and other compounds, causing a higher estrone:estradiol (E1:E2) ratio. This means oral doses are more subject to individual variances in enzymes and physiological chemistry. A high estrone ratio is linked to reduced skeletal growth in pubertal boys and insulin resistance in PCOS. The ratio is also known to be higher in early female puberty (~1:3), and lower in the later stages (~1:5). An average dose intramuscular injection can vary from far above to far below the average female range over the course of a week, depending on an individual's body.
Rainer Lisiewicz (1 July 2004 – 12 May 2009) Jörg Seydler (12 May 2009 – 29 November 2009) Uwe Trommer (29 November 2009 – 30 June 2010) – Caretaker Joachim Steffens (1 July 2010 – 7 June 2011) Mike Sadlo (7 June 2011 – 7 December 2011) Willi Kronhardt (3 January 2012 – 30 June 2012) Marco Rose (1 July 2012 – 30 June 2013) Carsten Hänsel (1 July 2013 – 23 September 2013) Heiko Scholz (8 October 2013 – 23 September 2018) Björn Joppe (27 September 2018 – 17 December 2018) Rainer Lisiewicz (18 December 2018 – 19 October 2019) Wolfgang Wolf (20 October 2019 – 30 June 2020) Almedin Civa (1 July 2020 – 19 February 2024) Tomislav Piplica (19 February 2024 – 30 June 2024) Jochen Seitz (1 July 2024 – 30 June 2026) Torsten Ziegner (since 1 July 2026 –)
Sources: en.wikipedia.org
Solvents can have a powerful effect on solubility, stability, and reaction rate. A change in solvent can also allow a chemist to influence the thermodynamic or kinetic control of the reaction. Reactions proceed at different rates in different solvents due to the change in charge distribution during a chemical transformation. Solvent effects may operate on the ground state and/or transition state structures. An example of the effect of solvent on organic reactions is seen in the comparison of SN1 and SN2 reactions. Solvent can also have a significant effect on the thermodynamic equilibrium of a system, for instance as in the case of keto-enol tautomerizations. In non-polar aprotic solvents, the enol form is strongly favored due to the formation of an intramolecular hydrogen-bond, while in polar aprotic solvents, such as methylene chloride, the enol form is less favored due to the interaction between the polar solvent and the polar diketone. In protic solvents, the equilibrium lies towards the keto form as the intramolecular hydrogen bond competes with hydrogen bonds originating from the solvent.
Because dextromethorphan (DXM) acts predominantly as the parent compound rather than through dextrorphan in Auvelity, the contribution of the active metabolite can largely be disregarded when analyzing Auvelity's pharmacological effects. Dextrorphan primarily provides NMDA channel blockade. However, DXM itself exhibits its strongest activity as a serotonin transporter (SERT) inhibitor and σ1 receptor agonist, while its NMDA antagonism is actually quite weak. In Auvelity, the conversion of DXM to dextrorphan by the CYP2D6 enzyme is substantially inhibited by bupropion, resulting in extremely high plasma concentrations of the parent DXM. Consequently, Auvelity's NMDA receptor antagonism is clinically quite limited, whereas σ1 receptor agonism and SERT inhibition become the dominant pharmacological actions. Based on pharmacokinetic data, it can be inferred that DXM in Auvelity may achieve approximately 60–85% whole-brain SERT occupancy, a level comparable to that of most SSRIs (selective serotonin reuptake inhibitors). In addition, σ1 receptor agonism, which was previously investigated as a target for antidepressant development, likely contributes to Auvelity's therapeutic efficacy. Bupropion produces relatively strong inhibition of the norepinephrine transporter (NET) and achieves approximately 14–28% dopamine transporter (DAT) occupancy, making it an NDRI (norepinephrine-dopamine reuptake inhibitor). Bupropion also antagonizes nicotinic acetylcholine receptors, acts as a weak positive allosteric modulator of the σ1 receptor, and inhibits 5-HT3 receptors.
== Music video == The shoot for the music video was released on YouTube on September 30 by Mike & Rocco (reality). The video was set to premiere on January 5, 2009 but leaked on December 31, 2008 and was officially released on January 1, 2009 via MTV Jams.
== Historiography == Berger, Henry W. ed. A William Appleman Williams Reader (1992). Ferrell, Robert H. Harry S. Truman and the Cold War Revisionists. (2006). 142 pp. excerpt and text search. Fitzpatrick, Sheila. "Russia's Twentieth Century in History and Historiography," The Australian Journal of Politics and History, Vol. 46, 2000. Gardner, Lloyd C. (ed.) Redefining the Past: Essays in Diplomatic History in Honor of William Appleman Williams (1986). Garthoff, Raymond L. "Foreign Intelligence and the Historiography of the Cold War." Journal of Cold War Studies 2004 6(2): 21–56. ISSN 1520-3972 Fulltext: Project MUSE. Isaac, Joel; Bell, Duncan, eds. Uncertain Empire: American History and the Idea of the Cold War (2012) online review by Victoria Hallinan. Kaplan, Lawrence S. American Historians and the Atlantic Alliance, (1991) online edition.. Kort, Michael. The Columbia Guide to the Cold War (1998). Matlock, Jack E. "The End of the Cold War" Harvard International Review, Vol. 23 (2001). Melanson, Richard A. "Revisionism Subdued? Robert James Maddox and the Origins of the Cold War" Political Science Reviewer, Vol. 7 (1977). Melanson, Richard A. Writing History and making Policy: The Cold War, Vietnam, and Revisionism (1983). Olesen, Thorsten B.Ed. The Cold War and the Nordic Countries: Historiography at a Crossroads. Odense: U Southern Denmark Press, 2004. Pp. 194. online review. Stephanson, Anders. American Imperatives: The Cold War and Other Matters, Verso Books, 2025 Suri, Jeremi.
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
The lyophilised powder is typically held at -20 C or lower in a dry, dark place. Reconstituted solutions are aliquoted and frozen to avoid repeated freeze-thaw cycles.